1 / 48

Anticoagulation 101

Anticoagulation 101. Neil A. Lachant, MD Chief, Section of Hematology Director, Thrombosis Program Cooper Cancer Institute Professor of Medicine UMDNJ Robert Wood Johnson Medical School. Venous Thrombosis Magnitude of the Problem. No national data Incidence 1- 2/1,000

jerry-murphy
Download Presentation

Anticoagulation 101

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Anticoagulation 101 Neil A. Lachant, MD Chief, Section of Hematology Director, Thrombosis Program Cooper Cancer Institute Professor of Medicine UMDNJ Robert Wood Johnson Medical School

  2. Venous ThrombosisMagnitude of the Problem • No national data • Incidence • 1- 2/1,000 • 300,000 - 600,000 new cases per year • increasing as population ages • life expectancy 78 years

  3. Incidence of VTE

  4. Manifestations • 2/3 DVT • 50- 80% post-phlebitic syndrome • 1/3 pulmonary emboli • 30% mortality • 30,000 – 60,000 deaths per year

  5. A 22 yo female presents with an iliofemoral DVT. Her aPTT is 37 sec (nl <32) and she is found to have a lupus anticoagulant. She weighs 55 kg and her creatinine is 0.5 mg/dl. She is started on weight -based UFH. Her aPTT at 4 hrs is 123 s. She could be anticoagulated by all of the following EXCEPT: 1. Decrease UFH with aPTT goal of 1.5-2.5 x her baseline 2. UFH monitoring heparin level 3. UFH correlating heparin level with the aPTT • LMWH without monitoring • Fondaparinux without monitoring

  6. A 22 yo female presents with an iliofemoral DVT. Her aPTT is 37 sec (nl <32) and she is found to have a lupus anticoagulant. She weighs 55 kg and her creatinine is 0.5 mg/dl. She is started on weight -based UFH. Her aPTT at 4 hrs is 123 s. She could be anticoagulated by all of the following EXCEPT: 1. Decrease UFH with aPTT goal of 1.5-2.5 x her baseline 2. UFH monitoring heparin level 3. UFH correlating heparin level with the aPTT • LMWH without monitoring • Fondaparinux without monitoring

  7. Heparin Therapy in APLS • Lupus anticoagulant with prolonged baseline aPTT • use LMWH • use standard weight-based unfractionated heparin dosing 1. correlate aPTT with heparin level (3-4 points) use aPTT range that corresponds to therapeutic heparin level (0.3 – 0.7 iu/ml) 2. follow thrombin time if standardized in your lab

  8. Patient Normal

  9. A 34 year old African American male presents with a femoral DVT. He is given a 5000 u bolus of UFH and is started on a heparin drip at 1000 u/hr. The aPTT remains subtheraputic despite an increase to 1800 u/hr. A hematology consult is obtained on the 3rd hospital day for “inability to be anticoagulated”.

  10. What is the most appropriate goal for UFH: • aPTT ratio 1.5 - 2.5 x baseline • aPTT that correlates with heparin level of 0.3 - 0.7 u/ml • Whatever the lab computer says the therapeutic range is

  11. What is the most appropriate goal for UFH: • aPTT ratio 1.5 - 2.5 • aPTT that correlates with heparin level of 0.3 - 0.7 u/ml • Whatever the lab computer says the therapeutic range is

  12. Effect of Thromboplastin on aPTT Ranges (Anti-Xa 0.3 - 0.7 IU/ml)

  13. Effect of Thromboplastin on aPTT Ranges (Anti-Xa 0.3 - 0.7 IU/ml)

  14. Review of the patients records shows that he weighs 150 kg. His current aPTT is 38 sec (normal < 37.1) with an infusion rate of 1800 u/hr. The most appropriate rate for the UFH infusion is: 1. 2700 u/hr (18 u/kg/hr) 2. 2000 u/hr (18 u/kg/hr capped for patient size) 3. Continue at 1800 u/hr 4. Switch to LMWH because UFH doses above 2000 u/hr are too dangerous to use

  15. Review of the patients records shows that he weighs 150 kg. His current aPTT is 38 sec (normal < 37.1) with an infusion rate of 1800 u/hr. The most appropriate rate for the UFH infusion is: 1. 2700 u/hr (18 u/kg/hr) 2. 2000 u/hr (18 u/kg/hr capped for patient size) 3. Continue at 1800 u/hr 4. Switch to LMWH because UFH doses above 2000 u/hr are too dangerous to use.

  16. UFH Dosing Adopted from Raschke Arch Int Med 156:1645, 1996

  17. Utilization management is pushing for discharge, but his INR is only 1.6. The most appropriate recommendation for the use of enoxaparin would be: 1. 150 mg (1 mg/kg) sc q 12 hr 2. 150 mg sc q 12 hr and check a heparin level immediately before the third dose 3. 150 mg sc q 12 hr and check a heparin level 3.5 - 4 hours after the third dose 4. 225 mg (1.5 mg/kg) sc q 24 hr 5. Enoxaparin contraindicated in a patient this large

  18. Utilization management is pushing for discharge, but his INR is only 1.6. The most appropriate recommendation for the use of enoxaparin would be: 1. 150 mg (1 mg/kg) sc q 12 hr 2. 150 mg sc q 12 hr and check a heparin level immediately before the third dose 3. 150 mg sc q 12 hr and check a heparin level 3.5 - 4 hours after the third dose 4. 225 mg (1.5 mg/kg) sc q 24 hr 5. Enoxaparin contraindicated in a patient this large

  19. Kinetics of LMWH • Different for each LMH • Doses not interchangable

  20. Low Molecular Weight Heparin Dosing

  21. LMWH in Obesity • Relationship of intravascular volume and TBW is not linear • adipose tissue has a relative decrease in plasma volume compared to muscle • could lead to overdosing

  22. Weight in LMWH Studies Actual weight dosed anti-Xa activity is not significantly increased in obesity

  23. Recommendations For the Use of LMWH in Obesity • Patient should receive LMWH dose based on actual body weight • if < 150 kg, • monitoring not necessary on a routine basis • if > 150 kg, • check heparin level 3.5 - 4 hrs after 3rd or 4th dose • dose reduce if > 1.0 IU/ml

  24. A 24 yo dialysis dependant female is paraplegic. She receives enoxaparin 1 mg/kg q 12h for an acute DVT. One week later in rehab, she develops pain in her right shoulder. She is brought to the emergency room during the night with a 20 cm hematoma in her right supraclavicular fossa. What is her correct enoxaparin dose? A. 1 mg/kg q 12h B. 1 mg/kg qd C. Enoxaparin contraindicated with ESRD

  25. A 24 yo dialysis dependant female is paraplegic. She enoxaparin 1 mg/kg q 12h for an acute DVT. One week later in rehab, she develops pain in her right shoulder. She is brought to the emergency room during the night with a 20 cm hematoma in her right supraclavicular fossa. What is her correct enoxaparin dose? A. 1 mg/kg q 12h B. 1 mg/kg qd C. Enoxaparin contraindicated with ESRD

  26. LMWHDosing in Renal Dysfunction • LMWH accumulates as Ccr decreases • cutoff point varies between different LMWHs • Ccr 30 - 50 • monitor heparin level if concern about dosing or bleeding • Ccr < 30 • dose reduce • monitor heparin level • Ccr < 10 • do not use LMWH under any circumstances

  27. Enoxaparin Dosing with Renal Dysfunction

  28. A 24 year old Hispanic female presents to her local hospital with left calf pain. Duplex shows a popliteal DVT. Therapy with UFH is initiated on Saturday. She is discharged on Sunday. Her only anticoagulation is 12 mg warfarin which she is told to start at 6 PM that night. She presents to Cooper Hospital on Monday evening with a leg that is painful and swollen to the groin. Duplex shows a DVT extending to the iliac vein.

  29. Which of the following statements about anticoagulation after VTE is/are true? 1. Warfarin should only be given simultaneously with a heparin, DTI or other rapid acting anticoagulant 2. Warfarin should be started at a dose of 5 - 7.5 mg 3. Warfarin should be overlapped with heparin for a minimum of 5 days (no matter what the INR is) 4. Heparin should be stopped when the INR > 2.0 for 2 days or INR > 2.5 5. All of the above

  30. Which of the following statements about anticoagulation after VTE is/are true? 1. Warfarin should only be given simultaneously with a heparin, DTI or other rapid acting anticoagulant 2. Warfarin should be started at a dose of 5 - 7.5 mg 3. Warfarin should be overlapped with heparin for a minimum of 5 days (no matter what the INR is) 4. Heparin should be stopped when the INR > 2.0 for 2 days or INR > 2.5 5. All of the above

  31. A 60 year old female is taking a stable dose of coumadin as prophylaxis for atrial fibrillation (INR 2.6). She develops a UTI and is treated with bactrim. Two weeks later her INR is 6.9. She has no clinical bleeding. Her coumadin is held. The most appropriate adjunctive therapy would be: A. Transfuse 4-6 units FFP B. Transfuse 15 bags cryoprecipitate C. Vitamin K 0.5 mg sc x 1 D. Vitamin K 10 mg sc x 1 E. Vitamin K 10 mg sc x 3d F. Vitamin K 2.5 mg po x 1 G. No additional therapy is needed

  32. A 60 year old female is taking a stable dose of coumadin as prophylaxis for atrial fibrillation (INR 2.6). She develops a UTI and is treated with bactrim. Two weeks later her INR is 6.9. She has no clinical bleeding. Her coumadin is held. The most appropriate adjunctive therapy would be: A. Transfuse 4-6 units FFP B. Transfuse 15 bags cryoprecipitate C. Vitamin K 0.5 mg sc x 1 D. Vitamin K 10 mg sc x 1 E. Vitamin K 10 mg sc x 3d F. Vitamin K 2.5 mg po x 1 G. No additional therapy is needed

  33. Reversal of Warfarin • INR < 5.0, no bleeding • lower dose or • omit dose, restart at lower dose Chest June, 2008

  34. Reversal of Warfarin • INR > 5.0 but < 9.0, no significant bleeding • omit 1 or 2 doses and restart at lower dose, or • omit dose, give vitamin k 1-2.5 mg po, or • for rapid reversal (i.e., surgery) 3 - 5 mg po (INR should decrease in 24 hr) • can repeat vitamin k 1-2 mg po if goal not reached

  35. Reversal of Warfarin • INR > 9.0, no significant bleeding • hold warfarin • give vitamin K 2.5 - 5 mg po (INR should be significantly reduced in 24 - 48 hrs) • additional vitamin k po if needed • resume warfarin when INR therapeutic

  36. Reversal of Warfarin • Any INR > 3.0, serious bleeding • hold warfarin • vitamin k 10 mg slow iv infusion • repeat every 12 hours as needed • FFP, r-VIIa or prothrombin complex depending upon urgency of the situation

  37. Reversal of Warfarin • Any INR > 3.0, life threatening bleeding • hold warfarin • fresh frozen plasma, r-VIIa or prothrombin complex • vitamin k 10 mg slow iv infusion

  38. Warfarin Pearls • Coumadin if possible • If generic, keep track of brands • Dose adjustment • Think in terms of a week • New warfarin dose = current dose x goal INR current INR • New dose = 35 mg x 2.5/5.0 • New dose = 17.5 mg/week = 2.5 mg/day

  39. IVC FilterIndications • Recent proximal DVT, and • Contraindication to anticoagulation • current or recent active GI bleed • intracranial bleed in last 5 days • recent neurologic or ophthalmologic surgery • cerebral metasteses at risk for bleeding • seminoma, melanoma, renal cell, choriocarcinoma • planned major surgery in next 4 weeks • severe, prolonged thrombocytopenia • Recurrent pulmonary emboli while fully anticoagulated

  40. New Anticoagulants • Pentasaccharide • Fondaprinux (Arixtra) • Oral IIa inhibitors • ximelagatran • Oral Xa-inhibitors

  41. Fondaparinux (Arixtra)

  42. Theoretical Models for Differential Effects of Heparin and LMWH on Thrombin and Factor Xa Fondaparinux: 5 Saccharide Units Fondaparinux IIa AT AT Xa 5 5 Binds to AT but not to Thrombin Binds to AT

  43. New Anticoagulants • Fondaparinux (Arixtra) • Synthetic pentasaccharide • Selective anti-Xa inhibitor • no anti-IIa activity • PT or PTT are insensitive • Renal excretion • T1/2 17 – 20 hrs • Does not bind PF4 • One reported case of HIT

  44. FDA Approved • hip and knee surgery prophylaxis • treatment of DVT • treatment of PE when started in hospital • surgical DVT prophylaxis

  45. Fondaparinux dosing for DVT or PE • < 50 kg  5 mg qd sc • 50 – 100 kg 7.5 mg qd sc • >100 kg  10 mg qd sc • Dose modification • Ccr 30 – 50, use with caution • Ccr < 30, contraindicated

  46. Because of long half-life, anticoagulant effect may last for 2 – 4 days after stopping fondaparinux with normal renal function • Anti-Xa activity can be measured • ? <0.3 u/ml safe • R-VIIa if severe bleeding

More Related